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stroke located in the left hemisphere. 
IgG and IgM antibodies against TOSV 
were detected in a serum sample ob-
tained at that time. The patient was 
discharged 1 week later with slight 
aphasia.
The most relevant common signs 
observed in patients 1 and 2 were the 
ischemic complications. Few cases of 
complicated encephalitis with sequelae 
caused by TOSV have been described 
(5,6). Moreover, to our knowledge, 
persistent neurologic TOSV infection 
has not been reported. The immune 
status of these patients probably in-
ﬂ  uenced the clinical outcome in both 
patients and the delayed serologic re-
sponse in patient 1.
Patient 3, a 41-year-old woman, 
sought treatment for exanthema at her 
health care center in July 2004. Test 
results for IgM antibodies against ru-
bella, parvovirus B19, and Rickettsia 
conorii were negative. Speciﬁ  c anti-
TOSV IgM was detected. The infec-
tion was self-limited, and no signs of 
neurologic involvement were associ-
ated with the rash. This was the only 
case of anti-TOSV IgM detection in 
358 serum specimens analyzed from 
patients with nonneurologic syn-
dromes. Although this ﬁ  nding is not 
conclusive, it suggests that TOSV 
infection might be involved occasion-
ally in other mild syndromes. Two 
other cases of TOSV infection without 
neurologic involvement have been re-
ported elsewhere: febrile erythema in 
Italy (7) and an inﬂ  uenza-like illness 
in southern France (8).
The unusual manifestations of 
TOSV infection reported here oc-
curred in persons from rural areas 
within Granada Province, where se-
roprevalence rates have been shown 
to be higher than in urban areas (3). 
These data provide more information 
about this arboviral infection. Atypi-
cal TOSV infection could occur par-
ticularly in areas where the virus is 
endemic.
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Sporadic 
Oropouche Virus
Infection, Acre, 
Brazil
To the Editor: Oropouche virus 
(OROV), a member of the Bunya-
viridae family, Orthobunyavirus ge-
nus, Simbu serogroup, is transmitted 
to humans in urban areas by the bit-
ing midge Culicoides paraensis and 
causes epidemic acute febrile disease 
(1). Since its ﬁ  rst isolation in Trinidad 
in 1955 (2), OROV has been associ-
ated with large outbreaks in South and 
Central America; half a million cases 
have been described during the past 
45 years (1). The tripartite genome of 
OROV comprises single-strand, neg-
ative-sense large (L), medium (M), 
and small (S) RNAs that encode RNA 
polymerase, glycoproteins, and nu-
cleocapsid, respectively. Studies have 
indicated the existence of 3 genotypes 
of OROV circulating in Brazil: geno-
types I and II in the Amazon Basin and 
genotype III in the Southeast Region 
(3–5).
OROV causes explosive urban 
epidemics. Serologic evidence of ex-
posure to OROV in populations not 
affected by known outbreaks suggests 
that the virus circulates endemically 
(1). However, no sporadic infections 
have been reported. Here we report a 
sporadic OROV infection detected by 
clinical and laboratory surveillance of 
acute febrile illnesses in Acre, a state 
in the western Amazon region of Bra-
zil. From March 2004 through Octo-
ber 2006, we prospectively investigat-
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ed 69 febrile episodes in persons 6–60 
years of age (mean, 28.1 years) living 
in the town of Acrelândia (10°13′W, 
67°00′S) and surrounding rural areas 
(25.7% and 74.3% of the sample, re-
spectively).
Serum samples for reverse tran-
scription–PCR (RT-PCR) were stored 
in liquid nitrogen in the ﬁ  eld  and 
shipped on dry ice to the laboratory in 
São José do Rio Preto, 3,500 km south-
east of Acre. Because malaria and sev-
eral arboviruses are locally endemic (6), 
all patients were screened for malarial 
parasites by thick-smear microscopy 
and for ﬂ  aviviruses and alphaviruses 
by multiplex-nested RT-PCR (7). The 
samples negative for both malaria and 
other arboviruses were further tested 
for OROV with primers targeting the 
S segment of the OROV genome in a 
seminested RT-PCR strategy (R.V.M. 
Bronzoni et al., unpub. data; primers 
and protocol available from the au-
thors by request). The sample also was 
isolated in Vero cells, and the RT-PCR 
described by Moreli et al. (8) was used 
for conﬁ  rmation.
We sequenced amplicons by us-
ing the same primers used for RT-
heminested ampliﬁ  cation and by using 
BigDye Terminators version 3.1 (ABI, 
Foster City, CA, USA) in ABI377 au-
tomated sequencer. Sequences were 
edited by DSGene 2.0 (Accelrys, San 
Diego, CA, USA) and deposited in 
GenBank (accession no. EU561644). 
One (1.4%) of 69 samples tested for 
OROV by heminested PCR was posi-
tive. This sample (BR/2004/ACRE27) 
was collected from a male patient from 
a rural area in April 2004. Precautions 
were followed to avoid contamina-
tion; positive and negative controls 
were used in all reactions; and the pro-
cedure was reproduced several times. 
The patient had ill-deﬁ  ned, mild ﬂ  u-
like symptoms; low-grade fever; and 
nasal discharge but reported no head-
ache or other major symptoms. He re-
covered without complication.
We built a phylogenetic tree 
on the basis of the 522 nucleotide 
sequences (27–200 aa) of nucleo-
capsid protein gene of OROV sample 
BR/2004/ACRE27 and other Gen-
Bank sequences from different OROV 
genotypes. We used sequences from 
Aino, Akabane, and Tinaroo viruses 
as the outgroup. A phylogenetic analy-
sis was performed by the neighbor-
joining method by using the Kimura 
2-parameter nucleotide substitution 
model (9).
The tree showed 3 main clades, 
corresponding to genotypes I, II, and 
III, and BR/2004/ACRE27 grouped 
within genotype I strains (Figure). 
Both genotypes I and II have been de-
scribed in OROV outbreaks in Acre; 
genotype I, however, is found mostly 
in Pará in the eastern part of the Bra-
zilian Amazon region.
A baseline serologic survey in ru-
ral Acrelândia during March and April 
2004 detected antibodies to OROV in 
6 (1.7%) of 357 persons 5–90 years 
of age who were examined by mi-
croplaque hemagglutination inhibition 
(10). Because none of these persons 
had been exposed to known OROV 
outbreaks in Acre or elsewhere, these 
ﬁ  ndings further suggest the sporadic 
circulation of OROV in the area.
We describe a sporadic infection 
of OROV infection in the Amazon re-
gion of Brazil in a mildly symptomatic 
patient. The nucleocapsid gene of the 
isolate has been sequenced, placing it 
in the genotype I group, the most com-
monly found in the Amazon Basin. 
These data suggest that OROV circu-
lation may be sporadic and clinically 
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Figure. Phylogenetic tree of Oropouche virus strains; boldface shows the sample from 
the patient in this study. Phylogenetic tree was constructed from partial nucleocapsid 
gene sequence (522 nt, 27–200 aa) by neighbor-joining method implemented in MEGA 
3.0 software (9). Kimura 2-parameter nucleotide substitution model was used, and the 
reliability of the branching patterns was tested by 1,000 bootstrap pseudo replicates. 
Bootstrap values (%) are shown in main nodes. Aino, Akabane, and Tinaroo viruses were 
used as the out group. The scale bar represents 5% nucleotide sequence divergence. 
GenBank accession numbers are provided and are grouped by strain designation. GI, 
genotype I; GII, genotype II; GIII, genotype III.
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silent and, when not associated with 
outbreaks, most likely neglected by 
local physicians.
This work was supported by Fundação 
de Amparo à Pesquisa do Estado de São 
Paulo (FAPESP) (grant no. 04/11098-2) 
and Consello Nacional de Desenvolvi-
mento Cieniﬁ   co e Tecnológico (grant 
no. 401396/2004-5). RVMB received 
fellowships from FAPESP (grant no. 
05/03260-7). This work also was partially 
supported by the Viral Genetic Diversity 
Network (VGDN–FAPESP–Brazil).
Ana Carolina Bernardes Terzian, 
Roberta Vieira 
de Moraes Bronzoni, 
Betânia Paiva Drumond, 
Mônica Da Silva-Nunes, 
Natal Santos da Silva, 
Marcelo Urbano Ferreira, 
Márcia Aparecida Sperança, 
and Maurício Lacerda Nogueira
Author afﬁ  liations: Faculdade de Medicina 
de São José do Rio Preto, São Paulo, Bra-
zil (A.C. Bernardes Terzian, R.V. de Moraes 
Bronzoni, M.L. Nogueira); IBILCE, São 
José do Rio Preto (A.C. Bernardes Terzian); 
Universidade Estadual de Montes Claros, 
Montes Claros, Brazil (B.P. Drumond); In-
stituto de Ciências Biológicas/Universidade 
de São Paulo, São Paulo (M. Da Silva-
Nunes, N. Santos da Silva, M.U. Ferreira); 
and Faculdade de Medicina de Marília, São 
Paulo (M.A. Sperança)
DOI: 10.3201/eid1502.080401
References
  1.   Pinheiro  FP,  Travassos  da  Rosa  APA, 
Vasconcelos PFC. Oropouche fever. In: 
Feigin RD, editor. Textbook of pediatric 
infectious diseases. Philadelphia: WB 
Saunders Co.; 2004. p. 2418–23.
  2.   Anderson CR, Spence L, Downs WG, Ait-
ken THG. Oropouche virus: a new human 
disease agent from Trinidad, West Indies. 
Am J Trop Med Hyg. 1961;10:574–8.
  3.   Saeed MF, Wang H, Nunes M, Vasconce-
los PF, Weaver SC, Shope RE, et al. Nu-
cleotide sequences and phylogeny of the 
nucleocapsid gene of Oropouche virus. J 
Gen Virol. 2000;81:743–8.
  4.   Nunes MR, Martins LC, Rodrigues SG, 
Chiang JO, Azevedo RSS, da Rosa AP, et al. 
Oropouche virus isolation, southeast Bra-
zil. Emerg Infect Dis. 2005;11:1610–3.
  5.   Azevedo RSS, Nunes MRT, Chiang JO, 
Bensabath G, Vasconcelos HB, Pinto 
AYN, et al. Reemergence of Oropouche 
fever, northern Brazil. Emerg Infect Dis. 
2007;13:912–5.
  6.   Silva-Nunes M, Malafronte RS, Luz BA, 
Souza EA, Martins LC, Rodrigues SG, et 
al. The Acre Project: the epidemiology of 
malaria and arthropod-borne virus infec-
tions in a rural Amazonian population. Cad 
Saude Publica. 2006;22:1325–34. DOI: 
10.1590/S0102-311X2006000600021
    7.   de Morais Bronzoni RV, Baleotti FG, 
Nogueira RMR, Nunes M, Figueiredo 
LTM. Duplex reverse transcription-PCR 
followed by nested PCR assays for de-
tection and identiﬁ   cation of Brazilian 
alphaviruses and ﬂ  aviviruses. J Clin Mi-
crobiol. 2005;43:696–702. DOI: 10.1128/
JCM.43.2.696-702.2005
  8.  Moreli  ML,  Aquino  VH,  Cruz  AC, 
Figueiredo LT. Diagnosis of Oropouche 
virus infection by RT-nested-PCR. J Med 
Virol. 2002;66:139–42. DOI: 10.1002/
jmv.2122
  9.   Kumar S, Tamura K, Nei M. MEGA3: in-
tegrated software for molecular evolution-
ary genetics analysis and sequence align-
ment. Brief Bioinform. 2004;5:150–63. 
DOI: 10.1093/bib/5.2.150
10.   Shope RE. The use of a micro-hemagglu-
tination test to follow antibody response 
after arthropod-borne virus infection in a 
community of forest animals. [Rio J]. Ann 
Microbiol. 1963;11:167–71.
Address for correspondence: Maurício Lacerda 
Nogueira, Laboratório de Pesquisas em 
Virologia, Departamento de Doenças Infecciosas 
e Parasitárias, Faculdade de Medicina de São 
José do Rio Preto—FAMERP, Av Brigadeiro 
Faria Lima 5416, São José do Rio Preto—
SP, Brazil 15090-000; email: mnogueira@
famerp.br
Meningitis Caused 
by Streptococcus 
suis Serotype 14, 
North America
To the Editor: Streptococcus suis 
is an opportunistic pathogen that can 
cause serious systemic infections in 
pigs and occupation-related infections 
in humans who work in close contact 
with pigs or pork by-products. Most S. 
suis organisms isolated from diseased 
pigs belong to serotypes 1–8 (1). The 
most prevalent strain worldwide is se-
rotype 2, which causes invasive infec-
tions in pigs and humans (2). We report 
a case of human meningitis caused by 
S. suis serotype 14.
The patient was a 59-year-old 
woman from rural Manitoba, Canada; 
she worked at a hog plant and handled 
300–400 piglets/day. In October 2007, 
when she sought care, she had a 2-day 
history of fever, vomiting, headache, 
neck pain, and reduced consciousness. 
She was febrile and confused and had 
meningeal signs. Leukocyte count 
was 19,900/mm3. Cerebrospinal ﬂ  uid 
(CSF) had 284 × 106/L leukocytes 
(59% lymphocytes, 41% polymorpho-
nuclear cells), 2.3 mmol/L glucose, 
and 1.85 g/L total protein. Gram stain 
of CSF showed gram-positive cocci 
in pairs; cefotaxime and vancomycin 
were prescribed empirically. Results 
of computed tomography of the head, 
chest radiograph, and transesophageal 
echocardiogram were within normal 
limits. Blood culture was negative af-
ter 5 days of incubation. The CSF cul-
ture grew small α-hemolytic colonies 
on blood agar and chocolate agar. The 
organisms were gram-positive cocci 
in chains, were catalase negative, and 
were identiﬁ  ed as S. suis by Vitek II 
and API 20 Strep System (both from 
bioMérieux, St.-Laurent, Quebec City, 
Canada).
Identiﬁ  cation of the organism as 
S. suis was conﬁ  rmed at the National 
Microbiology Laboratory, Winnipeg, 
Manitoba, Canada, by conventional 
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